Table 3.
Clinical trials targeting effectors of WNT/β-catenin pathway. Given the importance of the WNT/β-catenin pathway in cancer development, effectors of this pathway such as porcupine and LRP6 are specifically targeted in Phase 1 and 2 clinical trials in various cancers. Ad: adenovirus, DKK3: Dickkopf-related protein 3, RAF: rapidly accelerated fibrosarcoma, PD-1: Programmed cell death 1, EGFR: epidermal growth factor receptor.
| Intervention | Target | Condition or Disease | Sponsor | Phase | Submitted Date | Status | Identifier |
|---|---|---|---|---|---|---|---|
| Drug: LGK974 (Other names: WNT974, porcupine inhibitor) Biological: PDR001 (PD-1 monoclonal antibody) | Porcupine PD-1 | Pancreatic Cancer, BRAF Mutant CRC, Melanoma, Breast cancer (TNBC), Squamous Cell Cancers: head, neck, cervical, esophageal, lung | Novartis Pharmaceuticals | Phase 1 | 4 May, 2011 | Recruiting | NCT01351103 |
| Drug: WNT974 (porcupine inhibitor) Drug: LGX818 (RAF inhibitor) Biological: cetuximab (EGFR antibody) | Porcupine RAF EGFR | Metastatic BRAF Mutant CRC | Array BioPharma | Phase 1 Phase 2 | 6 October, 2014 | Completed | NCT02278133 |
| Drug: WNT974 (porcupine inhibitor) | Porcupine | Head and Neck Squamous Cell Cancer | University of Michigan Rogel Cancer Center | Phase 2 | 5 January, 2016 | Withdrawn | NCT02649530 |
| Biological: Ad-REIC/Dkk-3 (↑DKK3 expression) | Complex receptor (LRP6) | Prostate cancer | Momotaro-Gene | Phase 1 | 3 September, 2010 | Withdrawn (Suspended) | NCT01197209 |
| Drug: Ad5-SGE-REIC/Dkk3 (↑DKK3 expression) | Complex receptor (LRP6) | Prostate cancer | Momotaro-Gene | Phase 1 Phase 2 | 21 August, 2013 | Active, not recruiting | NCT01931046 |
| Drug: niclosamide (Antihelminthic) | Complex receptor (LRP6) | Colon cancer | M. Morse MD | Phase 1 | 10 February, 2016 | Recruiting | NCT02687009 |